Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

"LUT014 0.1% gel provides statistically significant benefit over placebo gel for the treatment of acneiform rash associated with cetuximab (Erbitux) or panitumumab (Vectibix) therapy for patients ...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Vectibix (panitumumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets ...

“Of those patients with the rash, two thirds had a dose impact on ... colorectal cancer who were receiving cetuximab or panitumumab and had developed grade 2 or noninfected grade 3 acneiform ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

Panitumumab, the first fully human antibody that targets the EGFR, significantly improved the progression-free survival of patients with metastatic colorectal cancer (CRC) in a phase III trial.

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...